Table 1. Summary of the infertility treatment after ovarian tissue transplantation.

Months after transplantation	MCD #3 E2, pg/mL; FSH, mIU/L; AMH, ng/mL	COS regimen, duration	Diameter of the developed follicles, mm	Peak E2, pg/mL	Results
3	E2 57; FSH 43.69; AMH 0.08	Natural cycle	RO 15	-	Cycle cancellation due to no further growth
5		CC 50 mg, 5 days	No growth	-	Cycle cancellation
7		CC 100 mg, 5 days	RO 15	41	Cycle cancellation due to no further growth
		→ LT 2.5 mg, 5 days
		→ hMG 225 IU, 3 days
		→ rFSH 225 IU, 10 days
10		CC 50 mg, 5 days	RO 18.5	276	Oocyte retrieved (GV × 1)
					Embryo transferred (6 cell grade III/IV × 1, on day 3)
					→ No pregnancy
11		LT 2.5 mg, 5 days	RO 16.5, 14, 13	168	Follicle ruptured before TVOA and changed to IUI
		→ CC 50 mg, 5 days			→ No pregnancy
		→ hMG 225 IU, 9 days
13		CC 50 mg, 5 days	RO 19	135	Follicle ruptured before TVOA and changed to IUI
		→ LT 2.5 mg, 5 days			→ No pregnancy
		→ hMG 75 IU, 1 days
14		CC 50 mg, 5 days	RO 17	88	No oocyte retrieved after TVOA
		→ hMG 225 IU, 3 days
15		CC 50 mg, 5 days	No growth	-	Cycle cancellation
		→ CC 100 mg, 5 days
		→ hMG 225 IU, 9 days
16		CC 50 mg, 5 days	No growth	-	Cycle cancellation
18	E2 89; FSH 42.06; AMH 0.03	CC 100 mg, 5 days	RO 17.5	314	No oocyte retrieved after TVOA
		→ CC 150 mg, 5 days
		→ hMG 150 IU, 2 days
19		CC 100 mg, 5 days	No growth	-	Cycle cancellation
		→ LT 2.5 mg, 5 days

MCD = menstrual cycle day, FSH = follicle-stimulating hormone, AMH = anti-microbial handwash, CC = clomiphene citrate, COS = controlled ovarian stimulation, GV = germinal vesicle, hMG = human menopausal gonadotropin (Menopur^®; Ferring SA, Madrid, Spain), IUI = intrauterine insemination, LT = Letrozole, rFSH = recombinant follicle-stimulating hormone (Gonal-F^®; Merck Serono, Darmstadt, Germany), RO = right ovary, TVOA = transvaginal oocyte aspiration.